Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO -0.92%34 FCF Yield % is -41.23 as of Jul. 15, 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Iconovo AB ranks worse than 90.53% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Iconovo AB's FCF Yield % or its related term are showing as below:
OSTO:ICO'
s FCF Yield % Range Over the Past 10 Years
Min: -203.78 Med: -9.71 Max: -1.17
Current: -41.23
During the past 10 years, the highest FCF Yield % of Iconovo AB was -1.17%. The lowest was -203.78%. And the median was -9.71%.
OSTO:ICO's FCF Yield % is ranked worse than 90.53% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.43
vs OSTO:ICO: -41.23
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Iconovo AB FCF Yield % Related Terms
Iconovo AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Iconovo AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Iconovo AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Iconovo AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iconovo AB (OSTO:ICO) has a FCF Yield % of -41.23 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Iconovo AB and its competitors. According to the industry distribution chart, Iconovo AB ranks #774 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 90.5%.
Is Iconovo AB's FCF Yield % too high?
Iconovo AB's current FCF Yield % is -41.23. Based on the distribution chart, Iconovo AB ranks #774 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #774 out of 855 companies for FCF Yield %. This places Iconovo AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Iconovo AB and its competitors. Iconovo AB's current FCF Yield % is -41.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr1.08 — trading 300% above its estimated fair value. The current FCF Yield % is -41.23. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current FCF Yield % is -41.23 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr1.08 is trading 300% above its estimated GF Value™ of kr0.27.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
FCF Yield %: -41.23
GF Value™: kr0.27 vs. price of kr1.08 (300% above fair value)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score
Get the complete analysis for OSTO:ICO
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
